Allarity Therapeutics (ALLR) Competitors $1.66 -0.20 (-10.75%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.66 0.00 (0.00%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. VXRT, CRVO, OKYO, ENTX, QNCX, WHWK, ATRA, ABOS, EXOZ, and IMUXShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Vaxart (VXRT), CervoMed (CRVO), OKYO Pharma (OKYO), Entera Bio (ENTX), Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Atara Biotherapeutics (ATRA), Acumen Pharmaceuticals (ABOS), eXoZymes (EXOZ), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Its Competitors Vaxart CervoMed OKYO Pharma Entera Bio Quince Therapeutics Whitehawk Therapeutics Atara Biotherapeutics Acumen Pharmaceuticals eXoZymes Immunic Allarity Therapeutics (NASDAQ:ALLR) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Does the media favor ALLR or VXRT? In the previous week, Vaxart had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 6 mentions for Vaxart and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.62 beat Vaxart's score of 0.53 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxart 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ALLR or VXRT more profitable? Allarity Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Vaxart's return on equity of -91.89% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -173.31% -102.57% Vaxart -122.63%-91.89%-38.40% Which has more volatility and risk, ALLR or VXRT? Allarity Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Do institutionals and insiders have more ownership in ALLR or VXRT? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, ALLR or VXRT? Allarity Therapeutics has higher earnings, but lower revenue than Vaxart. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$24.51MN/AN/AVaxart$47.40M1.88-$66.95M-$0.25-1.56 Do analysts prefer ALLR or VXRT? Allarity Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 442.17%. Vaxart has a consensus price target of $2.00, indicating a potential upside of 412.82%. Given Allarity Therapeutics' higher possible upside, equities research analysts clearly believe Allarity Therapeutics is more favorable than Vaxart.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVaxart beats Allarity Therapeutics on 7 of the 11 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.19M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.4375.4125.98Price / SalesN/A432.54515.86180.60Price / CashN/A46.6837.5660.44Price / Book1.029.6112.156.29Net Income-$24.51M-$53.29M$3.29B$271.07M7 Day Performance-15.74%0.13%0.74%3.87%1 Month Performance69.42%5.55%5.00%5.49%1 Year Performance-51.32%10.44%62.55%25.86% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics1.9644 of 5 stars$1.66-10.8%$9.00+442.2%-51.3%$27.19MN/A0.0010Short Interest ↑VXRTVaxart2.0381 of 5 stars$0.39+8.3%$2.00+412.8%-60.5%$89.28M$47.40M-1.44120Gap DownCRVOCervoMed3.8288 of 5 stars$9.62+3.2%$23.71+146.5%-49.5%$89.01M$9.74M-3.694Analyst RevisionOKYOOKYO Pharma2.148 of 5 stars$2.35+3.1%$7.00+197.9%+108.7%$88.39MN/A0.007Positive NewsShort Interest ↑ENTXEntera Bio1.5057 of 5 stars$1.93-0.5%$10.00+418.1%-9.5%$88.13M$180K-7.4220Positive NewsQNCXQuince Therapeutics3.718 of 5 stars$1.60+3.9%$8.14+408.9%+117.7%$85.94MN/A-1.4760News CoverageWHWKWhitehawk Therapeutics1.1848 of 5 stars$1.81+2.0%N/AN/A$85.07M$25.98M-30.0840ATRAAtara Biotherapeutics4.4485 of 5 stars$12.05-2.5%$21.00+74.3%+24.7%$84.63M$128.94M-28.02330Positive NewsABOSAcumen Pharmaceuticals2.7471 of 5 stars$1.36+3.8%$7.00+414.7%-49.2%$82.38MN/A-0.6020EXOZeXoZymes1.2226 of 5 stars$9.70flatN/AN/A$81.36M$70K0.0029Positive NewsIMUXImmunic2.0035 of 5 stars$0.82-5.7%$7.50+814.6%-47.7%$80.89MN/A-0.8770Gap Up Related Companies and Tools Related Companies Vaxart Alternatives CervoMed Alternatives OKYO Pharma Alternatives Entera Bio Alternatives Quince Therapeutics Alternatives Whitehawk Therapeutics Alternatives Atara Biotherapeutics Alternatives Acumen Pharmaceuticals Alternatives eXoZymes Alternatives Immunic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts